Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Corporation Stock Is Slumping Today

By George Budwell – Updated Jul 26, 2017 at 11:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Safety issues continue to cast doubt on the future of Dynavax's experimental hepatitis B vaccine.

What happened

Dynavax Technologies Corporation's (DVAX 0.00%) stock is slumping this morning after the FDA released the briefing documents for the company's experimental hepatitis B vaccine known as Heplisav-B. The vaccine is scheduled to be reviewed by a panel of experts this Friday. While the FDA isn't bound by the recommendation of the panel, it typically goes along with their guidance. As of 10:24 a.m. EDT, Dynavax's shares had fallen by as much as 17.6% on heavy volume, but they have since rallied, with the biotech's stock down only 1% at the time of writing. 

Dial indicating a high level of risk.

Image source: Getty Images.

So what 

The issue investors appear to be keying in on this morning is the noted imbalance in the number of deaths and cardiac events in the Heplisav-B trial arm, relative to the comparator vaccine, GlaxoSmithKline's Engerix-B. Put simply, Heplisav-B might be a riskier vaccine than the current standard of care, although the number of adverse events were too low to draw any firm conclusions, according to the FDA's own briefing document.  

Now what

While this safety issue is a real concern, there are two big reasons for investors to be optimistic heading into Friday's advisory committee meeting. First off, the briefing documents essentially confirm that Heplisav-B is an effective and highly robust vaccine. So, efficacy shouldn't be an issue come Friday. Next up, the safety signals detected in the FDA's analysis don't appear to be strong enough to scuttle a positive recommendation. A more likely scenario is that Dynavax will need to carry out a post-marketing monitoring program following approval.  

Is the stock worth buying heading into this binary event? According to some analysts, the biotech's shares could appreciate by over 300% if Heplisav-B is approved. While that's certainly a juicy value proposition, the flip side of the coin is that the biotech's shares will undoubtedly plunge if the opposite turns out to be the case. So, this stock isn't a great buy for conservative investors, but it may appeal to individuals that are comfortable with sky-high levels of risk. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.24 (0.00%) $0.00
GSK Stock Quote
GSK
GSK
$29.36 (-2.17%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.